- Home
- GNPX
GNPX
Genprex Inc.
as 05-15-2025 4:00pm EST
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 7.0M | IPO Year: | 2018 |
| Target Price: | $10.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $4.09 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Genprex Inc. News
GNPX Breaking Stock News: Dive into GNPX Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
PR Newswire
10 days ago
Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
PR Newswire
16 days ago
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
PR Newswire
17 days ago
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
PR Newswire
18 days ago
Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
PR Newswire
22 days ago
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
PR Newswire
24 days ago
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
PR Newswire
2 months ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Compare GNPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNPX Genprex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.